Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
about
CYP17 inhibitors in prostate cancer: latest evidence and clinical potentialAn Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate CancerPersistent androgen receptor addiction in castration-resistant prostate cancerAbiraterone in the management of castration-resistant prostate cancer prior to chemotherapyTargeting molecular resistance in castration-resistant prostate cancerDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesSuppression of LIM and SH3 Domain Protein 1 (LASP1) Negatively Regulated by Androgen Receptor Delays Castration Resistant Prostate Cancer Progression.Enzalutamide: a review of its use in chemotherapy-naïve metastatic castration-resistant prostate cancer.Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC).First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agentsEfficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone.Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancerNovel agents for castration-resistant prostate cancer: Early experience and beyond.The evolving role of enzalutamide on the treatment of prostate cancer.Managing Metastatic Castration-Resistant Prostate Cancer in the Pre-chemotherapy Setting: A Changing Approach in the Era of New Targeted Agents.Intracellular kinetics of the androgen receptor shown by multimodal Image Correlation Spectroscopy (mICS).The safety and efficacy of enzalutamide in the treatment of advanced prostate cancer.Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison.Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer.Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC).Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review.Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer.
P2860
Q26740070-0F154C42-D603-4E8C-8744-BD545226F336Q26744431-F383E613-C31A-41AC-BA91-C51AD7C41220Q26777163-80EFAB1A-6050-4FBE-888D-ACE45DEA5D71Q26786543-19458EF4-F84B-444B-8305-37255B1DAFFDQ26795445-E6D3BDC2-C28E-4062-AAD8-BAAB567D4DFCQ26796704-7FE6E2E1-65D5-4843-95A0-14250AA8BCBFQ30008838-61957499-C3B7-419E-B7EA-68E9B60F396BQ34464312-E1FDE403-E625-4222-AF18-5F6BE5F6D6BAQ34484835-77293228-2AAD-4CB1-A373-4CD032449F9BQ35879087-8B11CD6D-EFE6-4F0E-9273-E41773ED9740Q36055229-44742808-E131-4957-AEC3-5C2E770713D8Q36243639-F777EC04-5970-4E81-A02A-4E6BEF53439DQ36407003-C0E3FABB-B673-44D5-956D-B89F18753720Q36414184-C60F3F24-3A80-43CC-B727-F8573410E049Q36823062-AE26BA7F-96F3-4CD9-ADB2-4E6B46656DE8Q37496652-035A900C-20FD-43A7-9CF6-93B863859ABCQ37629545-99DADBFA-571C-4FB9-AFD0-418EF7823F91Q38276818-F331C55E-C4D7-41FA-9DA2-18B6D9F2CED8Q38574684-F8D7980D-8722-4B55-9A41-A4594A54FAAEQ38720976-F4E43AF3-F4B7-4E86-989A-C2E7D82C9BAAQ38731861-529074D0-15A3-418F-8424-AE842DBEE33CQ38744269-FA6F2F73-DEB4-4A66-8CA9-1FE4F48B1C39Q38841082-34D1DC80-AB21-4756-A8B8-92A97F1A2274Q38929688-876116BA-8E93-48C1-950C-6CF8712F2CC9Q40373904-08F13262-4567-42F7-A65C-4747CD9F4B13Q47121370-FEF082A8-7AEF-4ABF-BA70-C5641FA26377Q47269802-03853A31-AD4A-469F-9B68-C48C3487C547Q48107095-8DD7C375-9406-44EC-ADFF-0904749F451DQ55441916-08A9A2C7-ECF1-45C2-B283-B80565E1EE47
P2860
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Activity of enzalutamide in me ...... abiraterone and/or docetaxel.
@ast
Activity of enzalutamide in me ...... abiraterone and/or docetaxel.
@en
type
label
Activity of enzalutamide in me ...... abiraterone and/or docetaxel.
@ast
Activity of enzalutamide in me ...... abiraterone and/or docetaxel.
@en
prefLabel
Activity of enzalutamide in me ...... abiraterone and/or docetaxel.
@ast
Activity of enzalutamide in me ...... abiraterone and/or docetaxel.
@en
P2093
P2860
P356
P1476
Activity of enzalutamide in me ...... abiraterone and/or docetaxel.
@en
P2093
E S Antonarakis
H-T Rehman
J A Batten
M D Galsky
P2860
P2888
P304
P356
10.1038/PCAN.2014.53
P577
2015-01-20T00:00:00Z
P5875
P6179
1024877315